About
Theravance Biopharma is a biopharmaceutical company with one approved product, VIBATIV® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies. In addition, they have an economic interest in future payments that may be made by GlaxoSmithKline plc (GSK) pursuant to its agreements with Theravance, Inc. relating to certain drug programs, including the combination of umeclidinium (UMEC), vilanterol (VI) and fluticasone furoate (FF) (UMEC/VI/FF), the combination of the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) GSK961081 (‘081) and FF (‘081/FF), and MABA monotherapy.
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 31 investors are based in South San Francisco, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- South San Francisco, US
Contact Information
Find more investors like Theravance
Search Investors